The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...

NULISA employs a sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Purpose: The basic concepts of pharmacogenetics, pharmacogenetic study approaches, factors to consider when applying pharmacogenetic discoveries to patient care, and potential roles for ...